Search
Search
Invitrogen
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promotions']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.viewpromo']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promocode']}}: {{promo.promoCode}} {{promo.promoTitle}} {{promo.promoDescription}}. {{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.learnmore']}}
PA1-27780 detects SEI1 from human samples.
PA1-27780 may be successfully used in Western blot applications. By Western blot, this antibody has only been tested on fusion protein.
The immunogen is a synthetic peptide corresponding to human SERTA domain containing 1 variant.
SEI-1, also known as SERTAD1 (SERTA domain containing 1) or TRIP-Br1 (Transcriptional regulator interacting with the PHD-bromodomain 1), is a transcriptional regulator that integrates signals provided by transcription factors. Acting at E2F-responsive promoters, SEI-1 interacts with the PHD- and bromodomains of proteins such as TIF1 and DP-1, thereby transmitting their signals to the promoter and stimulating transcriptional activity. SEI-1 exists as a multiprotein complex with E2F-1 and DP-1 and is expressed at different levels throughout the cell cycle, allowing it to regulate cell cycle progression via promoter control during the G1 and S phases. Additionally, SEI-1 can render the activity of the cyclin D-Cdk4 complex, an important catalyst of the cell cycle, resistant to the inhibitory effects of p16. Overexpression of SEI-1 is implicated in the development of squamous cell carcinomas of the head and neck.
仅用于科研。不用于诊断过程。未经明确授权不得转售。